1. Introduction {#sec0005}
===============

Amongst those in treatment for opiate addiction, use of non-prescribed drugs is very common. Hair samples from 99 recently deceased opiate addiction patients identified a range of 21 different drugs being used during treatment, including cocaine, amphetamine, morphine and diazepam ([@bib0205]). Other studies have observed that over a third of patients entering opiate addiction treatment were also DSM-IV dependent on a drug other than heroin (not including nicotine) ([@bib0245]), and poly drug use has been reported to be as high as 68% ([@bib0305]). These high levels of drug use are not limited to illicit substances. Tobacco smoking is highly prevalent in drug treatment in general ([@bib0080]), with prevalence rates of over 90% observed in individuals undergoing methadone treatment for opiate addiction ([@bib0020], [@bib0060]). Methadone itself has been linked to increased tobacco cigarette consumption, smoke intake and self-reported satisfaction of cigarette smoking ([@bib0045]), and to increased alcohol consumption compared with heroin use ([@bib0010]).

Use of non-prescribed drugs during methadone treatment for opiate addiction has been associated with a range of adverse effects such as poor treatment retention and outcomes ([@bib0190]). Use of a single drug during opiate addiction treatment is associated with a threefold greater risk of dropping out of treatment, and use of multiple drugs quadruples the risk of dropping out ([@bib0320]). For example, cocaine use during methadone treatment has been linked to persistence of heroin use ([@bib0140]). Similarly, tobacco smoking during opiate detoxification results in significantly greater opiate craving and significantly lower rates of detoxification completion ([@bib0195]) and is associated with higher levels of illicit drug use ([@bib0120]).

High prevalence rates and the links to adverse treatment outcomes indicate a need for effective interventions for non-prescribed drug use during opiate addiction treatment. One of the most widely used behavioural interventions is contingency management (CM). CM is based on the theory of operant conditioning ([@bib0295]), which states that the administering of a reward for a particular behaviour increases the likelihood of that behaviour being repeated. In the current context, CM uses rewards (vouchers, clinical privileges or desirable items to be won as prizes for example) to positively reinforce abstinence from or reduced use of drugs during treatment for opiate addiction. CM differs from other common psychological interventions in that the focus of treatment is not on introspective analysis of discrepancies between goals and behaviour (as in motivational interviewing) or modification of flawed cognitive processing (as in CBT), but instead on directly influencing the reinforcement mechanisms involved in addiction ([@bib0150]). Previous reviews have shown CM to be moderately effective in treating substance use (illicit drugs, alcohol and tobacco) disorders in general ([@bib0015], [@bib0085], [@bib0100], [@bib0185], [@bib0235]), particularly so for opiate addiction ([@bib0235]). Despite a number of recent reviews assessing the efficacy of CM for substance use in general, very little is known about the use of CM for treating use of non-prescribed drugs in the context of opiate addiction treatment, where treatment outcomes may differ.

Whilst some of these reviews included studies assessing the use of CM in this context ([@bib0015], [@bib0040], [@bib0085], [@bib0185]), none directly addressed the efficacy of CM for substance use during opiate addiction treatment. The most recent review of this specific use of CM is a meta-analysis published over 16 years ago ([@bib0125]). CM was observed to perform better overall than control, and the effects of CM for drug use during opiate addiction treatment were observed to be moderated by five factors (type of reinforcer, time to reinforcement delivery, targeted CM drug(s), number of urine specimens collected per week and type of subject assignment). However, this review did not search the literature systematically, increasing the risk of bias in the selection of study data. Similarly, it did not assess the effects of different drugs targeted with CM, instead only assessing the moderating effects of targeting single or poly drug use. The aim of the present review was to assess the efficacy of CM for treating the use of different non-prescribed drugs during treatment for opiate addiction, by systematically searching the literature and assessing the effects of potentially moderating variables.

2. Method {#sec0010}
=========

A protocol for the current review is available online (see appendix of Supplementary file).

2.1. Search strategy {#sec0015}
--------------------

The review was carried out in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines ([@bib0200]). Studies were identified using a keyword search of the online databases Embase; PsychInfo; PsychArticles using the Ovid SP interface and a MeSH search of Medline using the PubMed interface; with the following search terms: "Contingency Management" **or** "Reward" **or** "Payment" **or** "Incentive" **or** Prize" **and** "Substance" **or** "Misuse" **or** "Drug" **or** "Narcotic\*" **or** "Tobacco" **or** "Smok\*" **or** "Stimulan\*" **or** "Cocaine" **or** "Alcohol" **and** "Opiate" **or** "Opioid" **or** "Heroin" **or** "Methadone". The search was limited to studies published between each database's inception and March 2015; published in the English language and including only humans. See appendix^1^ for full search strategy.

2.2. Inclusion and exclusion criteria {#sec0020}
-------------------------------------

Studies were eligible for inclusion if they: *i)* Tested one or more CM intervention(s) aimed at substance use reduction or abstinence in patients receiving treatment for opiate addiction. CM included any intervention that consistently administered rewards to positively reinforce substance use reduction or abstinence in patients receiving treatment for opiate addiction; *ii)* used a controlled trial design--either a no/delayed treatment control group or an alternative therapy control group, or controlled by repeated participation in two or more treatment arms; *iii)* randomised participants to conditions*; iv)* provided reinforcement or punishment contingent on biological verification of substance use/abstinence; *v)* used consistent measures of substance use at baseline and follow-up; *vi)* Published in a peer reviewed journal. Studies were excluded if: *i)* Participation was non-voluntary -- e.g., court orders, prison inmates etc.; *ii*) means and standard deviations for treatment effects were not available from the published data or the authors.

2.3. Study selection {#sec0025}
--------------------

Studies were reviewed for inclusion by three independent reviewers, with all studies being reviewed for inclusion twice. TA processed all titles and abstracts as first reviewer, RC and LB jointly processed half each as second reviewers. An agreement rate of 96% was reached between reviewers; disagreements were discussed and resolved by a separate reviewer, AM.

2.4. Quality assessment {#sec0030}
-----------------------

The 'Quality Assessment Tool for Quantitative Studies' ([@bib0105]) was used to assess the internal and external validity of all studies, as well as any biases and confounds. This assesses the quality of studies as strong, moderate or weak on six domains (selection bias, study design, confounds, blinding, data collection and withdrawals/dropouts), providing an overall score for the quality of the evidence in the study. A study is rated as providing strong evidence only when all domains are rated as moderate or strong, and a moderate rating when strong or moderate ratings are achieved for all bar one of the domains. Inter-rater reliability has been shown to be 'fair' across the six domains and 'excellent' overall, often performing better than the Cochrane Collaboration Risk of Bias Tool ([@bib0005]).

2.5. Data extraction and synthesis {#sec0035}
----------------------------------

All data extraction was completed by a single reviewer (TA) using an extraction table designed specifically for the current review and agreed by all reviewers (see supplementary materials). Where studies did not contain means and standard deviations for treatment effects, authors were contacted up to two times to obtain the data. Requests for data were sent to authors of 35 studies, with data for six studies being received ([@bib0035], [@bib0090], [@bib0115], [@bib0175], [@bib0220], [@bib0315]). Where means and standard deviations were not obtained, alternative data including F tests, *t*-tests and chi square were used to calculate an effect size where feasible ([@bib0095], [@bib0280], [@bib0290], [@bib0285]).

2.6. Outcome measures {#sec0040}
---------------------

Standardised mean differences (Cohen's *d* ([@bib0075])) were calculated for each individual study using either: 1) longest duration of abstinence (LDA) data or 2) percentage of biochemically verified negative samples (PNS). As follow-up data were available for only three of the 10 studies that included a follow-up period, all data used in analyses are those recorded during treatment.

2.7. Moderators {#sec0045}
---------------

A number of possible moderators were assessed, based on those shown in previous reviews to impact on the efficacy of CM ([@bib0125], [@bib0235]). These included the drug targeted for intervention, the decade in which the study was carried out, the quality of the study, duration of the intervention, the type of reinforcer used, and the form of opiate treatment participants were undergoing. Some moderators previously suggested to affect the efficacy of CM ([@bib0125], [@bib0235]) could not be investigated due to a lack of suitable data in the included studies or because all studies used the same approach. For example, the number of times abstinence was verified per week could not be investigated as 16 studies recorded this three times a week compared to only five recording it twice a week and one study recording it every day. Similarly, type of incentive (positive, negative, mixed) was not tested as all bar two studies in both analyses used a mixed incentive. Time to reinforcement could not be tested as all included studies delivered immediate reinforcements.

2.8. Data analysis {#sec0050}
------------------

Meta-analyses were carried out using RevMan v5.3 ([@bib0070]) software. Data were entered into a generic inverse variance analysis in RevMan that analysed the efficacy of CM compared with control across all drug use during treatment for opiate addiction, using both LDA and PNS. All meta-analyses were carried out as random effects analyses due to the wide variety of CM interventions included ([@bib0250]). To allow comparison of CM to control, some multi-arm trials were collapsed into a two-arm design by averaging the effects across the treatment conditions ([@bib0065]). This was only done however when each arm used CM in isolation (other than normal pharmacological treatment for opiate addiction); if a study arm included CM in combination with another behavioural or pharmacological treatment not part of standard treatment, then this arm was not included in the meta-analysis. This was done in order to match the design of the included studies with only single experimental and control arms. Control arms were not collapsed unless each was a standard treatment control. For example, one study ([@bib0275]) had four conditions (CM with either methadone or buprenorphine and performance feedback with either methadone or buprenorphine), so the two CM conditions were collapsed together, as were the two performance feedback conditions. Another study ([@bib0240]) also had four conditions (CM, methadone increase, CM + methadone increase and a usual care control), but no conditions were collapsed and only the CM and usual care control conditions were used in the analysis. The *I^2^* statistic was used to assess the percentage of variability in treatment effect estimates attributable to between-study heterogeneity.

Moderator analysis was performed using Comprehensive Meta-analysis software V.3 ([@bib0025]). Results were computed using random effects statistics and indicate the extent to which each moderator accounts for variability in effect sizes with respect to drug use outcomes. A significant value of Q-between indicates significant differences among effect sizes between the categories of the moderator variable. This method also calculates the mean pooled effect size for each category within the moderator variable being tested and whether this is significant. For the drug targeted for intervention, studies fell into five categories: opiates, cocaine, opiates and cocaine combined, tobacco, and polysubstance use. For study decade, studies were grouped as being published from 1990 to 1999, 2000 to 2009 and 2010 onwards (study publication dates ranged from 1993 to 2015). Study quality followed the strong, moderate and weak ratings of the 'Quality Assessment Tool for Quantitative Studies' ([@bib0105]). Intervention durations were grouped as \<12 weeks, 12 weeks, and \>12 weeks. Reinforcer type was categorised as monetary vouchers and 'other'. Opiate treatment similarly contained two categories, methadone treatment and 'other'.

Publication bias was assessed using the 'failsafe N' technique ([@bib0260]), calculated using Comprehensive Meta-analysis software V.3 ([@bib0025]). This calculates the number of studies averaging a Z-value of zero that would be required to make the overall pooled effect size non-significant ([@bib0260]).

3. Results {#sec0055}
==========

3.1. Included studies {#sec0060}
---------------------

A total of 3144 studies were identified in the search, yielding a total of 22 studies meeting inclusion criteria and included in the meta-analysis ([@bib0055], [@bib0050], [@bib0090], [@bib0095], [@bib0115], [@bib0110], [@bib0130], [@bib0155], [@bib0160], [@bib0165], [@bib0170], [@bib0180], [@bib0210], [@bib0225], [@bib0220], [@bib0215], [@bib0240], [@bib0275], [@bib0290], [@bib0285], [@bib0310], [@bib0315]) (see PRISMA flow diagram, [Fig. 1](#fig0005){ref-type="fig"}). The included studies randomised a total of 2333 patients to 39 CM conditions and 33 non-CM control conditions. This included three studies with two CM conditions each collapsed into a single CM condition, four studies with three CM conditions each collapsed into a single CM condition, and two studies with two CM, and two control, conditions each collapsed into single CM and control conditions.Fig. 1PRISMA flow diagram.Fig. 1

3.2. Study description and quality assessment {#sec0065}
---------------------------------------------

Eight of the 22 studies tested the effects of CM for cocaine use, two for opiate use, one for tobacco smoking, six for combined use of opiates and cocaine and five for polysubstance use. Twenty-one studies included some form of opiate substitution therapy (18 methadone, one buprenorphine, one a mixed buprenorphine and naloxone tablet, and one suboxone), with only a single study not utilising any form of opiate substitution therapy. The duration of CM interventions used ranged between 11 days and 31 weeks, with the number of participants in each study ranging between 12 and 388. Seventeen studies reported retention rates, resulting in an average retention rate of 76.4% (range 51.2%--97.7%). All studies were carried out in the US, with 13 being carried out in the same state (Maryland) (See [Table 1](#tbl0005){ref-type="table"} for full description of studies and interventions). Methodological quality assessment rated two studies as overall providing strong evidence, 10 studies moderate evidence and 10 studies weak evidence ([Table 2](#tbl0010){ref-type="table"}).Table 1Description of each included study and intervention, organised by drug target of CM intervention.Table 1Study, publication date, publishing journal and location carried outDesign and usual opiate substitution therapy treatmentParticipants randomised pre and post interventionIntervention procedureCM Schedule, length of intervention and max rewardAdditional treatmentsPrimary OutcomeAbstinence CriteriaSubstance use post interventionSubstance use at longest follow upCocaine[@bib0110]2 × 2 factorial design. CM or no CM, and CBT or Social supportRand − 193Urines collected every Mon, Wed and Fri, and vouchers administered dependent on conditionEscalating with reset and bonus for three consecutive negative samplesIndividual counselling sessions focussing on cessation of all drugsNumber of drug negative urinesBenzo \<300 ng/mlThroughout intervention, BZE levels were lower in the CM-only and combination groups than in the other two groups. F(1, 185) = 15.94, p \< 0.001No significant difference between any of the groups at 12 month follow upPsychology of Addictive Behavior Baltimore, Maryland, USAMeth., between 50 and 80 mg/dayPost − 14712 WeeksMax \$1155[@bib0155], [@bib0160]Rand − 40Multiple Each phase lasted 11 days50% reduction in Benzo. or Benzo \<300 ng/mlExperimental and Clinical Psychopharmacology Baltimore, Maryland, USARepeated measures − single, continuous, interrupted or no voucher meth. 100 mg/dayPost − Not reportedUrines collected Mon, Wed and Fri. Vouchers awarded dependent on condition (one large voucher, continuous or interrupted vouchers, or no voucher)Max reward dependent on conditionWeekly individual and group counsellingNumber of consecutive days cocaine abstinenceLDAMean abstinence duration was 2 days for no voucher, 3.2 days for single-voucher, and 4.9 and 4.8 days for continuous and interrupted voucher conditions, respectively, F(3, 117) = 7.3, p = \< 0.001.N/AKidorf et al. (1993)Rand − 44Fixed scheduleDefinition not reported7 WeeksExperimental and Clinical, Psychopharmacology Baltimore, Maryland, USACM or Yoked Control group. Ppt were accepted into the 2 years meth. treatment once the exp had done so Meth. 50 mg/dayPost − 43Urines collected Mon, Wed and Fri. The single reward was awarded after two consecutive weeks of cocaine abstinence which had to occur within the 7 week probationary periodSingle reward of 2 years meth. treatmentGroup and individual counselling at least once per weekTwo consecutive weeks of cocaine abstinencePNS50% of CM and 14% of control achieved 2 weeks of continuous cocaine abstinence. No significant difference was found between conditions for the number of negative urines returnedNo significant difference between the two conditions was found for the proportion of cocaine negative urines submitted[@bib0220]Rand − 76Fishbowl or voucher escalating with reset.Not reportedJournal of Consulting and Clinical Psychology, Connecticut, USAPrize based (fishbowl) or voucher based CM, or standard care control Meth. Mean dose between 78.4 and 83 mg/day dependent on conditionPost − 59Urines collected twice per week with an average of 4 days between submissions. Negative samples resulted in draws from the prize earn, or vouchers.12 weeks Max up to \$300 and \$585 respectivelyWeekly individual and/or group counsellingCocaine abstinenceLDA and PNSFishbowl CM ppt achieved significantly greater LDA than control ppt. Voucher CM ppt did not.No significant difference between percentage of participants submitting negative samples in any condition at 9 months[@bib0290]Rand −59Escalating with reset, with bonuses in one condition. 12 weeksBenzo. \<300 ng/mlJournal of Consulting and Clinical Psychology Baltimore, Maryland, USAThree conditions, Escalating CM, Escalating CM with start bonus, and yoked control Meth. Mean dose 62 mg/dayPost − Average retention 10.3--11.3 weeks dependent on conditionUrines collected Mon, Wed and Fri. Vouchers dispensed after urines testedMax reward \$1950 without bonusesOffered weekly individual counsellingNot reportedLDABoth CM conditions achieved significantly longer durations of abstinenceDifference between CM groups and control remained significant at 8 weeks[@bib0285]Two conditions, escalating with reset CM and yoked controlRand − 37Urines taken Mon, Wed and Fri.Escalating with reset and bonus.Benzo. \<300 ng/ml12 weeksArchives of General Psychiatry, Baltimore, Maryland, USAMeth. 50 mg/dayPost − 89% of exp ppt and 83% of ctrl ppt retained for full 12 weeksVouchers given for abstinenceMax \$1155Weekly individual counselling (45 min per week)Not reportedLDAExp patients achieved significantly longer durations of sustained cocaine abstinence than ctrl ppt (F(1.35) = 13.5; p = \<0.001)No significant difference found between groups 4 weeks post intervention[@bib0310]2 × 2 Design. CM or Yoked control and Topiramate or placebo.Rand − 171Escalating with reset.Benzo. \<300 ng/mlDrug and Alcohol Dependence, Baltimore, Maryland, USAMeth. 100 mg/dayPost − 113Urines collected Mon, Wed and Fri. Vouchers awarded for abstinence31 weeks Max \$1155Weekly individual and group counsellingCocaine abstinence between weeks 9 and 20PNS and LDANo significant difference found between any of the conditionsN/A[@bib0315]Rand − 12Fixed, with a single voucher or cheque available in each condition.Benzo. \<300 ng/mlExperimental and Clinical Psychopharmacology2 × 4 design − 2 types of reward type (voucher or cheque) and 4 types of reward magnitude (\$0, \$25, \$50 or \$100) Meth., dose not reportedPost − Not reportedUrines collected Mon, Wed and Fri. Rewards were provided for evidence of abstinence Mon to Wed, on the Thur16 weeks (two 8 week periods) Largest voucher value \$100Group and individual counsellingNot reportedPNSNo main effect of incentive type. Planned comparisons found that high value cheques resulted in significantly greater abstinence than high value vouchersN/A  Opiates[@bib0180]4 conditions, 4 CM, CBT, CM + CBT and no behavioural treatment ControlRand − 202Fishbowl with escalating draws.Exact criteria not reportedAddiction, Los Angeles, USASuboxone, variable dosePost − 134Urines collected twice weekly, with escalating numbers of draws for vouchers dependent on drug free urines16 weeks Max initially \$2196, later reduced to \$14600CounsellingProportion of opiate negative urinesPNSMean number of consecutive opioid-negative UA results did not differ significantly by group.Same results 52 week follow up as post treatment[@bib0240]Rand − 120Escalating with reset.\<300 ng/ml opiates8 weeksArchives of General Psychiatry, Baltimore, Maryland, USA4 Conditions: CM, Increased meth. with non contingent vouchers, CM + meth. increase, usual treatment control with non contingent vouchers Meth. dose not reportedPost − 112Urines collected Mon, Wed and Fri. Vouchers administered for evidence of abstinenceMax \$554Weekly individual counsellingOpiate negative urine samplesPNS and LDALDA significantly increased with contingent vouchers (F(1116) = 10.02, p = 0.002)N/A  Cocaine and OpiatesChutuape et al. (2000)Rand − 53Escalating with reset.Drug and Alcohol Dependence, Baltimore, Maryland, USA3 conditions: CM with weekly or monthly urine testing, and a control where take home meth. was awarded randomly Meth. 60 mg/dayPost − 43Urines collected Mon, Wed and Fri. One urine randomly selected either weekly or monthly dependent on condition to decide whether vouchers awarded28 weeks Max reward was take home doses for all weeksWeekly individual and group counselling sessionsNot reportedNot reportedThe mean LDA was 10.5 (SD 8.9), 8.4 (SD 8.5), and 5.4 (SD 7) weeks for the Weekly, Monthly, and Random Drawings groups, respectively (F(2.52) 1.9, PB0.16).N/A[@bib0115]Rand − 252Escalating with reset.\<300 ng/ml for both opiates and cocaineDrug Alcohol Dependence, Baltimore, Maryland, USA3 × 2 dose by contingency design − meth. dose of either 70 mg or 100 mg and yoked control, CM for cocaine or split CM for cocaine and opiatesPost − 23% of ppt dropped out before the end of the interventionUrines collected Mon, Wed and Fri. Vouchers were awarded for abstinence from cocaine and opiates either together or separately dependent on condition12 weeks Max not reportedWeekly individual counsellingPercentages of urine specimens negative for heroin, cocaine, and both simultaneouslyPNS and LDAMain effect of contingency on cocaine-negative urines, (F(2244) = 7.36, p = 0.0008) and on urines simultaneously negative for opiates and cocaine, (F(2244) = 3.61, p = 0.0285) but not in opiate-negative urines, (F(2244) = 2.51, p = 0.0830)N/AGroß et al. (2006)Three conditions: CM vouchers, Reduction in medication, and standard treatment controlRand − 60Escalating with reset and bonus.\<300 ng/ml of cocaine or opiatesExperimental and Clinical Psychopharmacology, Vermont, USABup, maintained on either 4 mg/70 kg or 8 mg/70 kg for the duration of the studyPost − 45Urines collected Mon, Wed and Fri. Dependent on condition, ppt either earned points, or did not have their bup dose decreased on evidence of abstinence12 weeks Max \$269Behavioural drug counsellingMean duration of continuous abstinence, total number of weeks abstinent (non-continuous), and number of missing visits.LDAContingent medication ppt achieved significantly greater durations of continuous abstinence (M = 5.9 weeks, SD = 4.6) than ppt in the voucher group (M = 2.9 weeks, SD = 3.3; Fisher's LSD, p=0.05).N/AKatz et al. (2002a,b)Two conditions, CM or Standard careRand − 52\<300 ng/ml for both opiates and cocaineExperimental and Clinical Psychopharmacology, Baltimore, Maryland, USAMeth. 100 mg/dayPost − Mean 35.9 days (of 180) in treatmentUrines collected three times per week and vouchers administered for negative samplesEscalating with reset and bonus 12 weeks Max \$1,087.50Weekly individual cognitive behavioural counsellingNot reportedLDA and PNSNo statistically significant condition effects foundN/APetry et al. (2002)CM or standared treatmentRand − 42Fishbowl, escalating draws.Not reportedJournal of Consulting and Clinical Psychology, Connecticut, USAMeth. Average 69 or 70 mg/day in standard treatment and CMPost − 39Urines collected Mon, Wed and Fri. Ppt received on draw for abstinence from either cocaine or opiates, and four for abstinence from both. Continuous weekly abstinence earned bonus draws12 weeks Max number of draws dependent on abstinence from different drugsMonthly individual counsellingWeeks of continuous abstinence from both opioids and cocaineLDAThere were significant group difference in the percentage of urine samples negative for both drugs (F(1, 40) = 4.01, p = 0.05The percentage of urine samples negative for both opioids and cocaine was higher in exp than ctrl ppt (U = 112.0, p=0.05.) at 6 month follow up[@bib0275]Rand − 162Escalating with reset.\<300 ng/ml for both opiates and cocaineThe American Journal of Psychiatry, USA2 × 2 design: meth. or buprenorphine and CM or performance feedback Maximum daily meth. dose of 85 mg or bup. dose of 16 mgPost − Cumulative proportion: meth. + CM − 0.6, meth. + performance feedback − 0.75, Bup + CM − 0.45, Bup + Performance feedback − 0.5Urines collected Mon, Wed and Fri and vouchers administered for evidence of abstinence24 week Max \$1033.50Individual counselling twice weekly for the first 12 weeks and weekly for the last 12Maximum number consecutive weeks of abstinence and proportion of drug-free urine testsLDAmeth. ppt achieved significantly longer periods of abstinence than bup. There were no significant effects of CM (F = 0.09, df = 1, 158, p = 0.76) and no significant interaction between medication and CM (F = 0.10, df = 1, 158, p = 0.75)N/A  Tobacco[@bib0095]Rand − 40Escalating with reset 90 daysExperimental and Clinical Psychopharmacology Vermont, USATwo conditions: CM and non contingent voucher Meth. 107.6 ± 8.8 mg/day or Bup. 14.9 ± 1.3 mg/dayPost − 25Biochemical verification taken everyday with vouchers for abstinence delivered daily. Numerous bonus\'s available for abstinence at certain pointsMax \$362.50None reportedPercentage of biochemical samples meeting abstinence criteriaAbstinence defined as breath CO ≤ 6 ppm during days 1--5 and a urine cotinine ≤ 80 ng/ml on Days 6--14 PNS and LDAExp. Ppt submitted significantly more negative samples than ctrl. Ppt (t (30.1) = 3.24, p \< 0.01)No significant difference between the two conditions at any follow up  Poly substance use[@bib0050]Two conditions: CM and usual care controlRand − 14\<200 ng/ml for meth., opiates, cocaine and benzodiazepinesDrug and Alcohol Dependence, Baltimore, Maryland, USAMeth. 71 mg/day or 77 mg/day in CM and standard care conditionsPost − 12Urines collected Mon, Wed and Fri. Vouchers or take homes administered for evidence of abstinence dependent on ppt choiceFixed. 12 weeks Max \$900 or three take homes per week dependent on ppt choiceTwice-weekly counselling sessions (one individual and one group session)Number of drug free urinesLDAmean LDA for exp ppt was 8.4 and 1 week for ctrl ppt (t(8) = 5.9, p = \<0.001.)5 ppt relapsed after the CM intervention. ended, generally within the first week[@bib0090]Two conditions: CM and Yoked controlRand − 41Urines taken Mon, Wed and Fri.Escalating with reset and bonus.\<300 ng/ml for all drugs other than phencyclidine which was \<25 ng/mlExperimental and Clinical Psychopharmacology, USAMixed Bup. Naloxone tablets. Dose not reportedPost − 21Vouchers administered for evidence of abstinence12 weeks Max not reportedWeekly cognitive behavioural substance abuse therapyNot reportedLDANo sig difference between the two groups on% drug free urines, LDA or total abstinence for heroin, cocaine or poly drug use during the voucher phaseN/AKidorf et al. (1996)Rand − 16Fixed with negative consequences for drug positive samples.Behavior Therapy, Baltimore, Maryland, USATwo conditions: CM and usual care control Meth. 60 mg/dayPost − 14Urines collected Twice per week and take homes administered for evidence of abstinence. Samples positive for drugs resulted in meth. being administered in a split dose2 month cross over Max 2 take homes per weekWeekly individual counsellingPercentage of drug free urinesBreath alcohol \< 0.5, other drug cut-offs not reported PNSA condition main effect was found, (F(2, 30) = 4.43, p = \< 0.05.) Patients submitted more drug-free urines when exposed to exp (M = 29%; SE = 9.0) than ctrl (M = 9%; SE = 3.0)N/A[@bib0210]Rand − 388Fishbowl, escalating with reset.Not reportedArchives of General Psychiatry USATwo conditions: CM and usual care control Meth. Doeses ranging between 67.9 mg/day to 108 mg/day dependent on recruitment centrePost − 67.1% of exp ppt and 64.8% ctrl ppt retainedUrines collected twice per week and prize draws allowed for evidence of abstinence12 weeks Max 204 draws, resulting in a maximum of approx. \$400 in prizes, plus one guaranteed \$20 prize.Individual and group consoling. Frequency ranged from 3 times per week to once per monthNot reportedLDAExp ppt were significantly more likely to submit stimulant- and alcohol-negative samples than were ctrl ppt (OR, 1.98; 95% CI, 1.42-2.77; missing samples coded as missing)No group differences in percentage of submitted samples negative for stimulants and alcohol (χ^2^ = 0.08, P=0.78).Petry et al. (2015)Rand − 240Escalating with reset for either fishbowl draws or vouchers dependent on condition.Not reportedJournal of Consulting and Clinical Psychology, USAFour conditions: \$300 prize CM, \$900 prize CM, \$900 voucher CM and usual care control Meth. Doses ranging between 77 mg/day and 85.4 mg/dayPost − Not reportedUrines taken at least twice a week with at least 2 days between tests. Abstinence resulted in either fishbowl draws or vouchers12 weeks Max either \$300 or 900\$Weekly group counsellingLDA and proportion of samples submitted negative for cocaine and alcoholPNS and LDAThe longest duration of abstinence and proportion of samples testing negative were significantly greater in each of the three CM conditions relative to usual care (F(3236) = 3.39, p = 0.02 and F(3236) = 3.94, p=0.009 respectively)At the 12-month follow-up, 113 of 225 (50.2%) patients submitted negative samples[^1]Table 2EPHPP ratings for all included studies organised by drug target of CM intervention.Table 2StudySelection BiasStudy DesignConfoundsBlindingData CollectionWithdrawals/ DropoutsOverallCocaine[@bib0110]211212Strong[@bib0155], [@bib0160]213211ModerateKidorf et al. (1993)311211Moderate[@bib0220]311312Weak[@bib0285]311211Moderate[@bib0290]211213Moderate[@bib0310]311112Moderate[@bib0315]313213Weak  Opiates[@bib0180]213212Moderate[@bib0240]313111Weak  Opiates and CocaineChutuape et al. (2000)311213Weak[@bib0115]311212ModerateGroß et al. (2006)311212Moderate[@bib0155], [@bib0160]211213ModeratePetry et al. (2002)211211Strong[@bib0275]311113Weak  Tobacco[@bib0095]211312Moderate  Poly-substance[@bib0050]313213Weak[@bib0090]333213WeakKidorf et al. (1996)313213Weak[@bib0210]311312WeakPetry et al. (2015)311213Weak[^2]

3.3. Meta-Analysis {#sec0070}
------------------

The meta-analysis for LDA (longest duration of abstinence) from all substances combined contained 18 studies randomising 2059 patients to 31 CM conditions and 25 non-CM control conditions. The random effects meta-analysis produced a pooled effect size of *d* = 0.57 (95% CI: 0.42--0.72), with CM performing significantly better than control ([Fig. 2](#fig0010){ref-type="fig"}). A moderate ([@bib0065]) level of the variability of effects between studies was due to between-study heterogeneity (I^2^ = 51%).Fig. 2Forest plot for LDA during treatment of all substances combined. (1) = Cocaine, (2) = opiates, (3) = opiates and cocaine, (4) = Tobacco, (5) = Poly-substance.Fig. 2

For PNS (percentage of negative samples), 12 studies randomising 1387 patients to 24 CM conditions and 21 non-CM control conditions were included and the pooled effect size was *d* = 0.41 (95% CI: 0.28--0.54), again with CM performing significantly better than control ([Fig. 3](#fig0015){ref-type="fig"}). Variability of effects was not due to between-study heterogeneity (I^2^ = 0%).Fig. 3Forest plot for PNS during treatment of all substances combined. (1) = Cocaine, (2) = opiates, (3) = opiates and cocaine, (4) = Tobacco, (5) = Poly-substance.Fig. 3

3.4. Moderator analysis {#sec0075}
-----------------------

The only moderator found to have a significant effect on the efficacy of CM was intervention drug target, but only for LDA ([Table 3](#tbl0015){ref-type="table"}, [Table 4](#tbl0020){ref-type="table"}). Within each of the categories of the six moderators, CM performed significantly better than control in all but three instances. Within drug targeted for intervention, CM performed no better than control for treating non-prescribed opiate use for both LDA and PNS. Within intervention duration, CM failed to encourage significantly better LDA than control in studies with intervention duration of less than 12 weeks. Within opiate treatment type, CM did not result in significantly greater PNS than control for studies where participants were in the 'other' category.Table 3Random effects moderator analysis results for LDA.Table 3Moderatork^1^Effect Size (d)^2^95% CIZ ValueP valueQ between (df)^3^P of Q betweenDrug targeted for intervention1810.75 (4)0.03Cocaine60.750.45--1.044.91\<0.001Opiates1−0.10−0.61--0.41−0.400.70Opiates and cocaine60.480.32--0.645.85\<0.001Tobacco11.020.37--1.673.10\<0.01Poly substance40.620.27--0.983.45\<0.01  Study decade1.31 (2)0.521990--199941.080.14--2.022.230.022000--2009100.530.41--0.658.67\<0.0012010 onwards40.530.32--0.744.92\<0.001  Study Quality2.66 (2)0.23Stong20.870.48--1.274.37\<0.001Moderate80.570.32--.824.47\<0.01Weak80.510.30--0.724.75\<0.001  Intervention Duration1.30 (2)0.52\<12 Weeks20.26−0.41--0.930.770.4412 Weeks120.630.44--0.826.42\<0.001\>12 Weeks40.530.27--0.794.04\<0.001  Reinforcer type0.0220.88Monetary Vouchers160.570.41--0.746.86\<0.001Other\'20.540.13--0.952.550.01  Opiate treatment0.650.42Methadone130.610.42--0.806.45\<0.001Other50.470.20--0.743.46\<0.01[^3]Table 4Random effects moderator analysis results for PNS.Table 4Moderatork^1^Effect Size (d)^2^95% CIZ ValueP valueQ betweeen (df)^3^P of Q betweenDrug targeted for intervention6.43 (4)0.17Cocaine40.40.13--0.672.89\<0.01Opiates30.18−0.11--0.461.230.22Opiates and cocaine20.430.18--0.673.42\<0.01Tobacco21.020.37--1.673.09\<0.01Poly substance10.490.23--0.743.74\<0.001  Study decade1.10 (2)0.581990--199920.510.25--0.773.83\<0.0012000--200930.300.01--0.592.010.052010 onwards70.400.20--0.603.93\<0.001  Study Quality0.36 (2)0.84Stong10.480.21--0.753.43\<0.01Moderate50.360.06--0.662.320.02Weak60.440.30--0.580\<0.001  Itntervention Duration0.32 (2)0.85\<12 Weeks50.470.28--0.674.73\<0.00112 Weeks20.420.18--0.673.350.04\>12 Weeks50.370.02--0.712.06\<0.01  Reinforcer type0.41 (1)0.52Monetary Vouchers90.390.23--0.544.82\<0.001Other\'30.510.17--0.852.94\<0.01  Opiate treatment0.35 (1)0.55Methadone80.450.30--0.606.00\<0.001Other40.32−0.08--0.721.580.12[^4]

3.5. Publication bias {#sec0080}
---------------------

There is widespread acceptance of the fact that studies reporting positive results are far more likely to be published than studies reporting null findings, resulting in an over representation of positive results within the literature ([@bib0265], [@bib0255], [@bib0270]). The 'failsafe N' ([@bib0260]) calculates the number of studies reporting null results that would be required to overturn the statistically significant difference between CM and control observed above. For LDA, 560 papers reporting null results would be required, and 101 for PNS.

4. Discussion {#sec0085}
=============

Overall, the random effects analyses showed CM performed significantly better than control in encouraging abstinence from a range of different drugs in patients undergoing treatment for opiate addiction. This was the case when measuring both LDA and PNS, producing medium and small ([@bib0075]) pooled effect sizes respectively. Moderator analysis performed on drug targeted for intervention, decade in which the study was carried out, quality of the study, duration of the intervention, type of reinforcer used, and form of opiate treatment, showed drug target for LDA data to be the only characteristic significantly moderating the efficacy of CM, driven primarily by the ineffectiveness of CM in treating opiate use. Despite only a single significant moderator effect, within each of the six moderator categories CM was found to perform significantly better than control in all but three cases. CM performed no better than control in encouraging abstinence from non-prescribed opiates during treatment for opiate addiction, measuring both LDA and PNS. CM also performed no better than control for LDA in studies with interventions less than 12 weeks long, and PNS in studies where usual opiate treatment was anything but methadone treatment. CM for other non-prescribed drug use in treatment for opiate addiction had no negative impact on usual treatment retention compared to three-month follow-up retention rates observed in usual opiate treatment ([@bib0030], [@bib0135], [@bib0300]).

This review has a number of limitations. One aim of the moderator analysis was to analyse the effects of CM by target drug type. To improve on the work of [@bib0125], five categories of drugs were used rather than two. However, one of them, polysubstance use, combined studies with four differing definitions of this, making results hard to integrate. CM still performed better in this category though, suggesting a robustness of effects across a variety of different drug combinations. Another limitation is that the review does not contain any grey literature. This means that any CM studies that have been conducted yet never published are not included in the analysis.

The current review does have a number of strengths however. It is the first review in over 16 years to address directly the efficacy of CM for encouraging abstinence from non-prescribed drug use during treatment for opiate addiction. This is important as CM has gained considerable support in this time, having been recommended since 2007 as a treatment for drug misuse by the National Institute for Health and Care Excellence ([@bib0230]). The findings of the current review support those of the previous reviews carried out in the field; finding an overall positive small to medium ([@bib0075]) effect size for CM in treating drug use in opiate addiction treatment ([@bib0125]). This is in contrast to the usual small effect size of psychological interventions in the field ([@bib0100]). Findings of the present review are also similar to those of a previous reviews assessing the use of CM for drug use overall, regardless of treatment setting which found similar small to medium effect sizes for drug use in general ([@bib0015], [@bib0040], [@bib0085], [@bib0185], [@bib0235]). The robustness of the effects of CM across different client groups suggests potential utility in treating a diverse range of individuals and needs within the addictions field.

We found no evidence of CM working better than control in encouraging abstinence from non-prescribed opiates during treatment, which is in contrast to [@bib0235] who identified CM as one of the most effective treatments for opiate use. The current review included only two studies of this type, compared to four (different) studies included in the previous review because of differing review aims. Moreover, three of the four opiate studies in the previous review systematically reduced methadone doses to zero over the course of the intervention, thereby increasing the likelihood of relapse to opiates and perhaps handing those receiving CM a competitive advantage over those not. Studies in the current review however maintained medication doses throughout the duration of the intervention, possibly eliminating this advantage and leading to the observed non-significant finding. With more data however, results for opiates may more closely follow the trends observed with other drugs.

The moderator analysis performed in the current review has also produced contradictory results to previous reviews. Previous reviews ([@bib0125], [@bib0235]) found four of the six moderators analysed here to have a significant effect on the efficacy of CM (drug targeted for intervention, the decade in which the study was carried out, the quality of the study evidence, the length of the intervention period). The current study only found a significant effect for drug targeted for intervention however. A possible explanation for this is differences in analysis, with the previous reviews adopting a fixed effects analysis, and the current the more conservative and more widely recommended ([@bib0065]) random effects analysis. Support for this comes from more recent reviews that have adopted this same random effects analysis. [@bib0185] for example analysed the effects of three (drug targeted for intervention, the decade in which the study was carried out, the quality of the study evidence) moderators also analysed in the current and previous reviews, finding none of them to have a significant effect.

More general limitations within the field have also been identified, for example a lack of data available for meta-analysis. In the current review, a total of 21 studies that met all other inclusion criteria could not be included in the quantitative data synthesis. This lack of available data is even more pronounced for follow-up, with only 10 of the 22 included studies utilising some sort of follow-up element in their study design, with data available for only three. CM is often criticised for poor follow-up results, but given the paucity of data we were not able to explore this here. Another concern is the quality of the studies included, with only two studies being rated as providing strong evidence, and 20 papers providing weak evidence. Notably, every study in the current review was performed in the US, with at least 13 performed in the same state and 17 having at least one co-author from the same institution. This significantly limits the generalisability of the currently available evidence on CM for non-prescribed drug use in opiate addiction treatment.

This lack of evidence does however present avenues for future research, particularly the use of CM for tobacco smoking in opiate addiction treatment. This is especially relevant considering that tobacco smoking is the most prevalent form of drug use in opiate addiction treatment ([@bib0020], [@bib0060]), and it has been shown that individuals in treatment for opiate addiction treatment have a mortality rate four times that of non-smokers ([@bib0145]). It is similarly important that future research studies are carried out in a wider range of countries, include follow-ups to investigate relapse after the removal of rewards, and focus on improving the overall quality of the data that are published.

In conclusion, CM appears to be an efficacious treatment of the use of cocaine, non-prescribed opiates and cocaine, tobacco, and polysubstance use during opiate addiction treatment, but not for use of non-prescribed opiates. Evidence about longer-term efficacy in this treatment context remains lacking, as is research into the effects of CM on tobacco, the most prevalent secondary addiction in this population.
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[^1]: Abbreviations -- **Rand**- Randomised to conditions, **Post**- Post intervention, **Exp** -- Experimental condition(s), **Ctrl** -- Control condition, **CM** -- Contingency Management, **TLFB** -- Time Line Follow Back, **LDA** -- longest duration of abstinence, **PNS** -- percentage of negative samples, **Meth.** -- methadone, **Bup.** -- buprenorphine, **Pbo.** -- placebo, **ppt** -- participants, **Benzo** -- benzoylecgonine, **OST** -- Opiate substitution therapy.

[^2]: 1 = Strong, 2 = Moderate, 3 = Weak

[^3]: ^1^Number of studies, ^2^Weighted random effects, ^3^A significant value of Q-between indicates significant differences among effect sizes between the categories of the moderator variable

[^4]: ^1^Number of studies, ^2^Weighted random effects, ^3^A significant value of Q-between indicates significant differences among effect sizes between the categories of the moderator variable.
